Trying To Bring Vaccine For 12-18 Age Group To India: Dr Reddy's

A senior executive of the drug maker said Phase 3 clinical trial data of Russia's single dose COVID-19 vaccine Sputnik Light has been submitted to the regulator and is awaiting approval.

Dr Reddy's Laboratories on Friday said it is in discussions with the Indian drug regulator to bring Russia's Sputnik M, a COVID-19 vaccine for the 12-18-year-old category, to India.

Addressing a press conference after announcing the company's Q3 results, a senior executive of the drug maker said Phase 3 clinical trial data of Russia's single dose COVID-19 vaccine Sputnik Light has been submitted to the regulator and is awaiting approval.

Deepak Sapra CEO - API and Services Dr Reddy's, also said the company is fully geared to make Molnupiravir, a COVID-19 drug both API and Formulations, at its facilities, even as it approached World Health organization for the prequalification of the drug.

"Sputnik M is a sputnik for adolescents. In Russia, Sputnik M has been given the approval by the regulator for children in the 12 to 18 years old group. The same data has been made available here. We are in the process of translating the data and we will be having a conversation with the regulator on this data within the next few months," Mr Sapra told reporters.